Physician profile
Patrick J Monteleone
NPI 1871595652
$11,478.48
in general payments reported to CMS, 2019-2025
31 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,522 · 2021: $1,769 · 2022: $2,545 · 2023: $988 · 2024: $1,309 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,660 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,660.39 |
| Education | $268.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,775.76 | 2019-2025 | |
| Abbott Laboratories | $1,424.64 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $1,076.51 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $1,021.42 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $669.88 | 2021-2025 | Verquvo, Winrevair, Steglatro |
| Amgen INC. | $613.46 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.32 | 2019-2025 | Jardiance |
| Pfizer INC. | $551.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $541.54 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $452.05 | 2022-2025 | Amvuttra |
| Boston Scientific Corporation | $400.74 | 2019-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $377.31 | 2023-2025 | Uptravi, Opsumit |
| Biotronik INC. | $276.21 | 2019-2020 | |
| Akcea Therapeutics, INC. | $274.71 | 2019-2021 | |
| Esperion Therapeutics, INC. | $255.67 | 2020-2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $220.70 | 2019-2024 | Camzyos |
| Amarin Pharma, INC. | $194.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $185.35 | 2019-2021 | |
| Novo Nordisk INC | $135.35 | 2021-2025 | Ozempic, Rybelsus |
| Chiesi USA, INC. | $78.57 | 2019-2021 | |
| Althera Pharmaceuticals LLC | $70.13 | 2021-2022 | |
| Vifor Pharma, INC. | $68.07 | 2020-2023 | Veltassa |
| Regeneron Healthcare Solutions, INC. | $67.60 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $34.68 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.48 | 2020-2021 | |
| Mannkind Corporation | $26.30 | 2025 | |
| Scpharmaceuticals INC. | $23.27 | 2023 | |
| Medtronic, INC. | $23.10 | 2023 | Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.87 | 2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $16.68 | 2023 | Inpefa |
| Lundbeck LLC | $16.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Monteleone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.